Skip to content
The Nexus
DossierENTITY

Kevin Ryan

Coverage of Kevin Ryan in the Nexus archive.

Earliest in view: Jul 15 · 08:59 UTCMost recent: Jul 15 · 08:59 UTC
Co-mentioned in this coverage
AlleyCorporganization1Transcend Therapeuticsorganization1Yale Center for Psychedelic Researchorganization1MongoDBorganization1Business Insiderorganization1Gilt Groupeorganization1Zolaorganization1
Recent coverage
  • BUSINESSJul 15 · 08:59 UTCFORTUNE
    Kevin Ryan’s AlleyCorp raises new $335 million fund, all in on early-stage bets

    Kevin Ryan’s AlleyCorp has raised a $335 million second fund focused on early-stage investments in healthcare, deep tech, and general tech. The firm, previously a family office, now has eight unicorns in its portfolio and has backed psychedelic research initiatives and companies like Transcend Therapeutics, which was sold for $1.2 billion.

Kevin Ryan · Dossier · The Nexus